Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
27M
-
Shares change
-
-3.04M
-
Total reported value, excl. options
-
$94.7M
-
Value change
-
-$19.3M
-
Number of buys
-
31
-
Number of sells
-
-42
-
Price
-
$3.51
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2022
81 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27M shares
of 98.6M outstanding shares and own 27.38% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8.74M shares), FMR LLC (3.79M shares), WASATCH ADVISORS INC (2.97M shares), Nextech Invest AG (1.91M shares), BlackRock Inc. (1.61M shares), Nantahala Capital Management, LLC (914K shares), VANGUARD GROUP INC (823K shares), RENAISSANCE TECHNOLOGIES LLC (671K shares), TWO SIGMA INVESTMENTS, LP (401K shares), and MORGAN STANLEY (386K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.